Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-REVERT
2021-006040-27Phase 2Active
- Sponsor
- Cardior Pharmaceuticals
- Start
- Feb 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of CDR132L in myocardial infarction (MI), left ventricular systolic dysfunction (LVSD) and heart failure (HF) (3 arms), sponsored by Cardior Pharmaceuticals. Primary endpoint: Percent change from baseline in LVESVI at Month 6. Started Feb 2022; status: active.
02
Drugs
CDR132L
03
Conditions
myocardial infarction (MI)left ventricular systolic dysfunction (LVSD)heart failure (HF)
Beyond the preview
Go deeper on 2021-006040-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006040-27.